Skip to content
Bored Studies
RecruitingPhase 2

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

NewAmsterdam Pharma · NCT06496243

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
69
US sites recruiting
1
Study start
December 2, 2024
Record last updated
April 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab

Patients will

Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16

Being studied: obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks

Conditions: Dyslipidemias

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Lp(a): >=50 mg/dL (>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) >= 20 mg/dL (>= 50 nmol/L) to \<50 mg/dL (\< 125 nmol/L) for cohort 2
  • LDL-C >70 mg/dL
  • TG \< 400mg/dL (\<4.52 mmol/L)

Exclusion Criteria

  • HbA1c>=10 or FPG >=270 mg/dL
  • CV events within 3 months of screen

Recruiting US locations

Study contacts (from the official record)

  • Ashley Walker · 919 641 5724 · ashley.walker@newamsterdampharma.com
All heart & blood pressure studies in Pennsylvania →
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels (NCT06496243) | Bored Studies